Shareholder_NN
information_NOMZ
Ownership_NN
structure_NN
Holdings_GER
by_PIN
size_NN
as_IN
at_PIN
31_CD
December_NN
2002_CD
%_NN
of_PIN
Number_NN
of_PIN
%_NN
of_PIN
Number_NN
of_PIN
ordinary_JJ
Size_NN
of_PIN
shareholding_GER
holdings_GER
total_VPRT
holdings_GER
ordinary_JJ
shares_NN
shares_NN
Over_IN
1,000,000_CD
105_CD
0.78_CD
533,599,190_CD
76.03_CD
100,001_CD
1,000,000_CD
384_CD
2.87_CD
120,864,910_CD
17.22_CD
10,001_CD
100,000_CD
901_CD
6.72_CD
29,290,396_CD
4.17_CD
5,001_CD
10,000_CD
677_CD
5.05_CD
4,704,777_CD
0.67_CD
1,001_CD
5,000_CD
4,694_CD
35.03_CD
9,882,074_CD
1.41_CD
501_CD
1,000_CD
3,333_CD
24.87_CD
2,493,286_CD
0.36_CD
1_CD
500_CD
3,307_CD
24.68_CD
977,450_CD
0.14_CD
13,401_CD
100.00_CD
701,812,083_CD
100.00_CD
Directors_NN
Mr_NN
R_NN
D_NN
Lapthorne_NN
CBE_NN
Chairman_NN
,_,
Chairman_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
Mr_NN
J_NN
Fr_NN
Odfjell_NN
Deputy_NN
Chairman_NN
,_,
Chairman_NN
of_PIN
the_DT
Nomination_NOMZ
Committee_NN
Sir_NN
William_NN
Castell_NN
Chief_NN
Executive_NN
Mr_NN
G_NN
W_NN
Battersby_NN
Human_NN
Resources_NN
Director_NN
Mr_NN
D_NN
H_NN
Brydon_NN
OBE_NN
Non-Executive_NN
Director_NN
,_,
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
Dr_NN
A_NN
Carr_NN
President_NN
,_,
Amersham_NN
Biosciences_NN
Mr_NN
J_NN
H_NN
Johansen_NN
Non-Executive_NN
Director_NN
,_,
employee_NN
representative_NN
Mr_NN
G_NN
F_NN
B_NN
Kerr_NN
Finance_NN
Director_NN
Mr_NN
P_NN
Loescher_NN
President_NN
,_,
Amersham_NN
Health_NN
Dr_NN
J_NN
S_NN
Patterson_NN
Non-Executive_NN
Director_NN
Professor_NN
Sir_NN
Keith_NN
Peters_NN
Non-Executive_NN
Director_NN
Mr_NN
J_NN
F_NN
Rejeange_NN
Non-Executive_NN
Director_NN
Professor_NN
E_NN
Thorsby_NN
Non-Executive_NN
Director_NN
Professor_NN
M_NN
Uhln_NN
Non-Executive_NN
Director_NN
Full_NN
details_NN
of_PIN
the_DT
Board_NN
and_CC
its_PIT
Committees_NN
are_VPRT [PASS]
given_VBN
on_PIN
pages_NN
36_CD
to_PIN
37_CD
._.
Secretary_NN
and_CC
registered_VBN
ofce_NN
Sub-registrar_NN
,_,
Norway_NN
Mr_NN
R_NN
E_NN
B_NN
Allnutt_NN
Den_NN
norske_NN
Bank_NN
,_,
ASA_NN
Amersham_NN
Place_NN
Registrar_NN
Department_NOMZ
Little_NN
Chalfont_NN
Postboks_NN
1171_CD
Buckinghamshire_NN
Sentrum_NN
HP7_NN
9NA_NN
0107_CD
Oslo_NN
Telephone_NN
44_CD
0_CD
1494 544000_CD
Norway_NN
Registered_NN
in_PIN
England_NN
Wales_NN
No_SYNE
1002610_NN
Telephone_NN
:_:
47_CD
22_CD
48_CD
1050_CD
http_NN
:_:
www_NN
._.
no_SYNE
Registrar_NN
and_CC
transfer_VB
ofce_JJ
US_FPP1
Depositary_NN
Lloyds_NN
TSB_NN
Registrars_NN
Citibank_NN
N._NN
A._NN
The_NN
Causeway_NN
111_CD
Wall_NN
Street_NN
Worthing_GER
21st_CD
Floor_NN
West_NN
Sussex_NN
New_NN
York_NN
10043_CD
BN99_NN
6DA_NN
Telephone_NN
:_:
1_CD
877 248 4237_CD
Telephone_NN
44_CD
0_CD
870 600 3998_CD
1-877-CITIADR_NN
http_NN
:_:
www_NN
._.
com_NN
adr_NN
Shareholder_NN
services_NN
Amersham_NN
plc_NN
offer_VPRT
a_DT
range_NN
of_PIN
shareholder_NN
services_NN
including_VBG [WZPRES]
direct_JJ
payment_NOMZ
of_PIN
your_SPP2
dividends_NN
into_PIN
your_SPP2
bank_NN
account_NN
,_,
payment_NOMZ
of_PIN
dividends_NN
in_PIN
foreign_JJ
currencies_NN
,_,
a_DT
dividend_NN
reinvestment_NOMZ
plan_NN
,_,
a_DT
corporate_JJ
ISA_NN
,_,
proxy_NN
voting_NN
on_PIN
line_NN
and_CC
the_DT
ability_NOMZ
to_TO
donate_VB
unwanted_JJ
shares_NN
to_PIN
charity_NOMZ
through_PIN
ShareGift_NN
._.
Please_VB
see_VB [PRIV]
enclosed_VBN
information_NOMZ
leaet_NN
for_PIN
further_JJ
details_NN
or_CC
call_VB
0870 600 3998_CD
or_CC
visit_NN
www_NN
._.
Financial_NN
calendar_NN
25_CD
April_NN
2003_CD
Record_NN
date_NN
in_PIN
UK_NN
,_,
Norway_NN
and_PHC
USA_NN
for_PIN
final_JJ
dividend_NN
7_CD
May_POMD
2003_CD
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
2_CD
June_NN
2003_CD
UK_NN
,_,
Norway_NN
and_PHC
US_FPP1
payment_NOMZ
of_PIN
final_JJ
dividend_NN
of_PIN
5.15_CD
p_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
July_NN
2003_CD
Announcement_NOMZ
of_PIN
results_NN
for_PIN
half_DT
year_NN
to_PIN
30_CD
June_NN
2003_CD
and_CC
of_PIN
interim_JJ
dividend_NN
November_NN
2003_CD
Payment_NOMZ
of_PIN
interim_JJ
dividend_NN
February_NN
2004_CD
Announcement_NOMZ
of_PIN
results_NN
for_PIN
year_NN
to_PIN
31_CD
December_NN
2003_CD
and_CC
of_PIN
proposed_VBN [SUAV]
final_JJ
dividend_NN
Amersham_NN
plc_NN
93_CD
Glossary_NN
angiogenesis_NN
the_DT
growth_NN
of_PIN
new_JJ
blood_NN
vessels_NN
supplying_VBG [WZPRES]
a_DT
tumor_NN
a_DT
potential_JJ
target_NN
for_PIN
diagnostics_NN
and_PHC
therapies_NN
aimed_VBN [WZPAST]
at_PIN
cutting_VBG
off_PIN
the_DT
blood_NN
supply_NN
and_CC
starving_VBG
the_DT
tumor_NN
anti-sense_JJ
drugs_NN
small_JJ
molecules_NN
that_TSUB
interfere_VPRT
with_PIN
the_DT
process_NN
of_PIN
protein_NN
production_NOMZ
._.
They_TPP3
are_VPRT [PASS]
designed_VBN
to_PIN
bind_NN
to_PIN
a_DT
specic_JJ
region_NN
of_PIN
the_DT
target_NN
messenger_NN
RNA_NN
,_,
thus_CONJ
preventing_VBG
the_DT
production_NOMZ
of_PIN
the_DT
protein_NN
molecule_NN
bioassay_NN
a_DT
biological_JJ
test_NN
or_CC
analysis_NN
,_,
used_VBN [PASTP]
in_PIN
high_JJ
throughput_NN
screening_VBG [WZPRES]
to_TO
test_VB
the_DT
effect_NN
of_PIN
potential_JJ
drug_NN
compounds_NN
on_PIN
target_NN
molecules_NN
implicated_VBN [WZPAST]
in_PIN
disease_NN
,_,
and_ANDC
to_TO
identify_VB
validate_JJ
lead_NN
compounds_NN
biopharmaceutical_VPRT
a_DT
drug_NN
eg_CONJ
._.
insulin_NN
based_VBN [WZPAST]
upon_PIN
biological_JJ
molecules_NN
such_JJ
as_IN
proteins_NN
,_,
which_WDT [SERE]
are_VPRT [PASS]
produced_VBN
in_PIN
cell_NN
culture_NN
and_CC
subsequently_TIME
separated_VBD
and_PHC
puried_VBD
through_PIN
chromatographic_JJ
and_CC
ltration_NOMZ
techniques_NN
bioprocess_NN
chromatography_NN
separations_NOMZ
media_NN
and_PHC
systems_NN
for_PIN
purifying_VBG
proteins_NN
a_DT
necessary_JJ
step_NN
in_PIN
the_DT
manufacture_NN
of_PIN
biopharmaceuticals_NN
brachytherapy_JJ
treatment_NOMZ
of_PIN
cancers_NN
by_PIN
close_JJ
range_NN
radiation_NOMZ
,_,
eg_CONJ
._.
through_PIN
radioactive_JJ
implants_NN
chromatography_VPRT
a_DT
technique_NN
used_VBN
to_TO
analyze_VB
or_CC
separate_JJ
molecules_NN
,_,
such_JJ
as_IN
proteins_NN
and_PHC
DNA_NN
coronary_JJ
angiography_NN
a_DT
scanning_VBG
procedure_NN
for_PIN
visualising_VBG
the_DT
arteries_NN
that_TSUB
supply_VPRT
the_DT
heart_NN
with_PIN
blood_NN
CT_NN
computed_VBD
tomography_NN
an_DT
X-ray_NN
technique_NN
that_TSUB
provides_VPRT
computer-generated_JJ
sliced_JJ
images_NN
of_PIN
the_DT
body_NN
cyclotron_NN
machine_NN
in_PIN
which_WDT [PIRE]
positively_RB
charged_VBD
particles_NN
are_VPRT [PASS]
accelerated_VBN
in_PIN
a_DT
spiral_NN
path_NN
in_PIN
a_DT
vacuum_NN
between_PIN
poles_NN
of_PIN
a_DT
magnet_NN
,_,
energy_NN
being_VBG [WZPRES] [BYPA]
provided_VBN
by_PIN
a_DT
high_JJ
frequency_NN
voltage_NN
across_PLACE
the_DT
vacuum_NN
used_VBN
to_TO
produce_VB
radioisotopes_NN
for_PIN
medical_JJ
purposes_NN
2D_VPRT
DIGE_NN
two-dimensional_JJ
uorescence_NN
difference_NN
in-gel_JJ
electrophoresis_NN
,_,
a_DT
proteomics_NN
research_NN
technology_NN
for_PIN
comparison_NN
of_PIN
protein_NN
expression_NN
samples_NN
from_PIN
normal_JJ
and_PHC
diseased_JJ
tissues_NN
,_,
and_ANDC
monitoring_VBG
the_DT
effect_NN
of_PIN
drugs_NN
on_PIN
the_DT
tissues_NN
DNA_NN
the_DT
genetic_JJ
material_NN
of_PIN
most_EMPH
living_VBG
organisms_NN
,_,
which_WDT [SERE]
contains_VPRT
heritable_JJ
characteristics_NN
packaged_VBN
deoxyribonucleic_JJ
acid_NN
in_PIN
genes_NN
electrophoresis_NN
separation_NOMZ
technique_NN
based_VBN [WZPAST]
on_PIN
the_DT
movement_NOMZ
of_PIN
suspended_VBN
particles_NN
through_PIN
a_DT
uid_NN
under_IN
the_DT
action_NOMZ
of_PIN
an_DT
electric_JJ
eld_NN
EMEA_NN
European_NN
Medicines_NN
Evaluation_NOMZ
Agency_NN
,_,
the_DT
regulatory_JJ
authority_NOMZ
in_PIN
the_DT
European_NN
Union_NN
endocardial_JJ
border_NN
visualisation_NOMZ
of_PIN
the_DT
surface_NN
of_PIN
the_DT
heart_NN
muscle_NN
,_,
for_PIN
improved_VBN
assessment_NOMZ
of_PIN
heart_NN
wall_NN
motion_NOMZ
delineation_NOMZ
in_PIN
ultrasound_NN
imaging_GER
enzymes_VPRT
any_QUAN
of_PIN
numerous_JJ
complex_JJ
protein_NN
substances_NN
that_TSUB
are_VPRT [BYPA]
produced_VBN
by_PIN
living_VBG
cells_NN
and_CC
bring_VB
about_RB
or_CC
accelerate_VB
reactions_NOMZ
:_:
enzymology_NN
,_,
the_DT
study_NN
of_PIN
enzymes_NN
,_,
their_TPP3
nature_NN
,_,
activity_NOMZ
and_PHC
signicance_NN
external_JJ
beam_NN
radiation_NOMZ
treatment_NOMZ
of_PIN
cancer_NN
by_PIN
irradiating_VBG
the_DT
tumor_NN
from_PIN
a_DT
source_NN
outside_PLACE
the_DT
body_NN
FDA_NN
Food_NN
and_PHC
Drug_NN
Administration_NOMZ
,_,
the_DT
regulatory_JJ
authority_NOMZ
in_PIN
the_DT
United_NN
States_NN
FDG_NN
uoro-deoxyglucose_NN
a_DT
sugar_NN
molecule_NN
labeled_VBN [WZPAST]
with_PIN
the_DT
radioisotope_NN
uorine-18_NN
,_,
a_DT
highly_AMP
sensitive_JJ
molecular_JJ
diagnostic_JJ
used_VBN
in_PIN
PET_NN
imaging_GER
gamma_NN
camera_NN
a_DT
scanning_VBG
instrument_NOMZ
that_TSUB
detects_VPRT
gamma_NN
rays_NN
emitted_VBN [WZPAST]
by_PIN
radiopharmaceuticals_NN
,_,
enabling_VBG [PRESP]
the_DT
visualisation_NOMZ
of_PIN
organ_NN
function_NOMZ
:_:
see_VB [PRIV]
SPECT_NN
genomics_NN
the_DT
study_NN
of_PIN
the_DT
genetic_JJ
material_NN
on_PIN
an_DT
organism-wide_JJ
basis_NN
eg_CONJ
._.
the_DT
human_JJ
genome_NN
is_VPRT [BEMA]
the_DT
set_NN
of_PIN
genes_NN
that_TSUB
code_VPRT
for_PIN
a_DT
human_JJ
being_NN
._.
Genomics_NN
includes_VPRT
the_DT
analysis_NN
of_PIN
gene_NN
function_NOMZ
,_,
gene_NN
expression_NN
see_VPRT [PRIV]
microarray_NN
and_CC
genetic_JJ
variation_NOMZ
see_VPRT [PRIV]
SNP_NN
high_JJ
throughput_NN
screening_VBG [WZPRES]
simultaneous_JJ
screening_GER
of_PIN
large_JJ
numbers_NN
of_PIN
drug_NN
candidates_NN
against_PIN
protein_NN
molecules_NN
implicated_VBN [WZPAST]
in_PIN
disease_NN
informatics_NN
the_DT
use_NN
of_PIN
powerful_JJ
computer_NN
technology_NN
software_NN
and_PHC
data_NN
management_NOMZ
systems_NN
for_PIN
the_DT
collection_NOMZ
,_,
storage_NN
,_,
analysis_NN
and_PHC
organization_NOMZ
of_PIN
very_AMP
large_JJ
amounts_NN
of_PIN
biological_JJ
data_NN
94_CD
Amersham_NN
plc_NN
Annual_JJ
Report_NN
&_CC
Accounts_NN
2002_CD
interferons_NN
a_DT
group_NN
of_PIN
proteins_NN
produced_VBD
naturally_RB
by_PIN
the_DT
cells_NN
of_PIN
our_FPP1
bodies_NN
,_,
which_WDT [SERE]
increase_VPRT
the_DT
resistance_NN
of_PIN
cells_NN
to_PIN
viral_JJ
infection_NOMZ
in_PIN
vitro_NN
biological_JJ
processes_NN
observed_VBD [PRIV]
outside_PLACE
the_DT
body_NN
,_,
eg_CONJ
._.
in_PIN
a_DT
test_NN
tube_NN
in_PIN
vivo_NN
biological_JJ
processes_NN
observed_VBD [PRIV]
in_PIN
a_DT
living_NN
organism_NN
left_VBD
ventricular_JJ
function_NOMZ
how_RB
well_RB
the_DT
left_VBN
ventricle_NN
of_PIN
the_DT
heart_NN
is_VPRT
doing_VBG [PROD]
its_PIT
job_NN
of_PIN
pumping_VBG
blood_NN
into_PIN
the_DT
aorta_NN
,_,
the_DT
great_JJ
trunk_NN
artery_NN
that_TSUB
carries_VPRT
blood_NN
from_PIN
the_DT
heart_NN
through_PIN
the_DT
body_NN
mass_NN
spectrometry_NN
analysis_NN
instrument_NOMZ
based_VBN [WZPAST]
on_PIN
the_DT
mass-to-charge_NN
ratio_NN
of_PIN
a_DT
substance_NN
metastasis_NN
spreading_VBG [WZPRES]
of_PIN
cancer_NN
from_PIN
the_DT
primary_JJ
tumor_NN
to_PIN
other_JJ
sites_NN
in_PIN
the_DT
body_NN
microarray_NN
a_DT
system_NN
consisting_VBG [WZPRES]
of_PIN
thousands_NN
of_PIN
minute_NN
samples_NN
of_PIN
genetic_JJ
material_NN
deposited_VBD
or_CC
synthesised_VBD
on_PIN
slides_NN
or_CC
biochips_NN
,_,
for_PIN
rapid_JJ
identication_NOMZ
and_PHC
analysis_NN
of_PIN
gene_NN
expression_NN
i._FW
e._FW
which_WDT
genes_NN
are_VPRT [PASS]
expressed_VBN
or_CC
active_JJ
in_PIN
normal_JJ
and_PHC
diseased_JJ
tissue_NN
,_,
or_CC
in_PIN
response_NN
to_PIN
drug_NN
treatment_NOMZ
monoclonal_JJ
antibody_NN
an_DT
antibody_NN
produced_VBN [WZPAST]
by_PIN
a_DT
single_JJ
type_NN
of_PIN
immune_JJ
cell_NN
which_WDT [WHSUB]
binds_VPRT
to_PIN
a_DT
specic_JJ
part_NN
of_PIN
its_PIT
protein_NN
target_NN
MRI_NN
magnetic_JJ
an_DT
imaging_GER
technology_NN
using_VBG [WZPRES]
radio_NN
waves_NN
and_CC
a_DT
magnetic_JJ
eld_NN
to_TO
produce_VB
high_JJ
resolution_NOMZ
images_NN
resonance_NN
imaging_GER
of_PIN
slices_NN
through_PIN
the_DT
body_NN
myocardium_NN
the_DT
middle_JJ
muscular_JJ
layer_NN
of_PIN
the_DT
heart_NN
wall_NN
myocardial_JJ
infarction_NOMZ
a_DT
term_NN
used_VBN
to_TO
describe_VB
irreversible_JJ
injury_NN
to_PIN
heart_NN
muscle_NN
neurology_NN
the_DT
study_NN
of_PIN
the_DT
nervous_JJ
system_NN
brain_NN
,_,
spinal_JJ
cord_NN
and_PHC
nerves_NN
non-Hodgkins_JJ
lymphoma_NN
a_DT
heterogeneous_JJ
group_NN
of_PIN
malignant_JJ
cancers_NN
of_PIN
the_DT
lymphatic_JJ
system_NN
non-ionic_JJ
in_CONJ
contrast_NULL
media_NN
,_,
a_DT
compound_NN
which_WDT [WHSUB]
does_VPRT
not_XX0
dissociate_VB
in_PIN
solution_NOMZ
and_ANDC
therefore_CONJ
has_VPRT
a_DT
low_JJ
osmolality_NOMZ
number_NN
of_PIN
particles_NN
in_PIN
a_DT
given_VBN
volume_NN
of_PIN
liquid_NN
._.
This_DEMP
reduces_VPRT
side_NN
effects_NN
and_PHC
discomfort_NN
upon_PIN
injection_NOMZ
,_,
particularly_RB
for_PIN
X-ray_NN
contrast_NN
media_NN
._.
nucleotide_IN
the_DT
building_GER
block_NN
of_PIN
DNA_NN
and_PHC
RNA_NN
oncology_VPRT
the_DT
study_NN
of_PIN
tumors_NN
:_:
cancer_NN
peptide_NN
a_DT
short_JJ
sequence_NN
of_PIN
amino_JJ
acids_NN
forming_VBG [WZPRES]
part_NN
of_PIN
a_DT
protein_NN
perfusion_NN
cardiac_JJ
how_RB
well_RB
the_DT
heart_NN
is_VPRT
being_VBG [PASS]
supplied_VBN
with_PIN
blood_NN
PET_NN
positron-emission_NN
a_DT
highly_AMP
sensitive_JJ
radiopharmaceutical_JJ
imaging_GER
technique_NN
eg_CONJ
._.
for_PIN
cancer_NN
,_,
where_RB
PET_NN
can_POMD
detect_VB
tomography_NN
very_AMP
early_TIME
signs_NN
of_PIN
the_DT
cancer_NN
spreading_VBG [WZPRES]
pharmacological_JJ
drugs_NN
administered_VBN
to_TO
make_VB
the_DT
heart_NN
work_NN
harder_RB
,_,
used_VBN [PASTP]
for_PIN
testing_GER
heart_NN
function_NOMZ
in_PIN
patients_NN
stress_NN
agents_NN
who_WP [WHSUB]
are_VPRT [BEMA]
unable_PRED
to_TO
exercise_VB
on_PIN
a_DT
treadmill_NN
preclinical_JJ
studies_NN
of_PIN
a_DT
potential_JJ
new_JJ
drug_NN
to_TO
determine_VB [SUAV] [PRIV]
its_PIT
safety_NN
,_,
metabolic_JJ
properties_NN
and_PHC
effectiveness_NOMZ
before_IN
it_PIT
can_POMD
be_VB [PASS]
administered_VBN
to_PIN
patients_NN
in_PIN
clinical_JJ
trials_NN
protein_NN
one_CD
of_PIN
the_DT
myriad_JJ
of_PIN
complex_JJ
molecules_NN
that_TSUB
control_VPRT
all_QUAN
cellular_JJ
functions_NOMZ
and_CC
are_VPRT [PASS]
coded_VBN
for_PIN
by_PIN
genes_NN
proteome_VPRT
all_QUAN
the_DT
proteins_NN
produced_VBD
from_PIN
all_QUAN
the_DT
genes_NN
of_PIN
a_DT
genome_NN
proteomics_NN
the_DT
study_NN
of_PIN
specic_JJ
proteins_NN
expressed_VBN [WZPAST]
in_PIN
cells_NN
and_PHC
tissues_NN
,_,
with_PIN
the_DT
aim_NN
of_PIN
determining_VBG [SUAV] [PRIV]
their_TPP3
function_NOMZ
and_CC
their_TPP3
role_NN
in_PIN
disease_NN
,_,
and_ANDC
identifying_VBG
potential_JJ
new_JJ
drug_NN
targets_NN
pulmonary_JJ
embolism_NN
the_DT
sudden_JJ
obstruction_NOMZ
of_PIN
a_DT
blood_NN
vessel_NN
in_PIN
the_DT
lung_NN
by_PIN
a_DT
blood_NN
clot_NN
that_TSUB
has_VPRT [PEAS]
circulated_VBN
in_PIN
the_DT
blood_NN
and_CC
lodged_VBN
in_PIN
the_DT
lungs_NN
radioisotope_VPRT
a_DT
radioactive_JJ
form_NN
of_PIN
a_DT
chemical_NN
element_NOMZ
Amersham_NN
plc_NN
95_CD
Glossary_NN
continued_VBD
radioimmunotherapy_JJ
a_DT
cancer_NN
treatment_NOMZ
that_TSUB
uses_VPRT
immune_JJ
system_NN
antibodies_NN
to_TO
carry_VB
cancer-killing_JJ
radioactive_JJ
agents_NN
directly_RB
to_PIN
tumor_NN
cells_NN
radiopharmaceutical_JJ
radioactively-tagged_JJ
compound_NN
necessary_JJ
to_TO
produce_VB
a_DT
nuclear_JJ
medicine_NN
image_NN
,_,
also_RB
called_VBD
a_DT
tracer_NN
or_CC
radionuclide_NN
renal_JJ
relating_VBG
to_PIN
the_DT
kidneys_NN
RNA_NN
ribonucleic_JJ
acid_NN
a_DT
chemical_NN
found_VBN [PRIV] [WZPAST]
in_PIN
the_DT
nucleus_NN
and_PHC
cytoplasm_NN
of_PIN
cells_NN
,_,
which_WDT [SERE]
plays_VPRT
an_DT
important_JJ
role_NN
in_PIN
protein_NN
synthesis_NN
and_CC
other_JJ
chemical_NN
activities_NOMZ
of_PIN
the_DT
cell_NN
._.
The_DT
structure_NN
of_PIN
RNA_NN
is_VPRT [BEMA]
similar_PRED
to_PIN
that_DEMO
of_PIN
DNA_NN
._.
There_EX
are_VPRT
several_QUAN
classes_NN
of_PIN
RNA_NN
molecules_NN
:_:
messenger_NN
RNA_NN
,_,
transfer_NN
RNA_NN
,_,
and_ANDC
ribosomal_JJ
RNA_NN
._.
sequencing_VBG
identifying_VBG
the_DT
order_NN
of_PIN
the_DT
letters_NN
nucleotides_NN
in_PIN
the_DT
DNA_NN
code_NN
SNP_NN
single_JJ
nucleotide_NN
very_AMP
small_JJ
genetic_JJ
differences_NN
between_PIN
individuals_NN
,_,
which_WDT [SERE]
may_POMD
affect_VB
disease_NN
susceptibility_NOMZ
and_PHC
polymorphisms_NN
response_NN
to_PIN
drugs_NN
SPECT_NN
single_JJ
photon_NN
a_DT
functional_JJ
imaging_GER
technique_NN
producing_VBG [WZPRES]
computer-generated_JJ
sliced_JJ
images_NN
of_PIN
the_DT
body_NN
based_VBN
emission_NN
computed_VBN [WZPAST]
on_PIN
the_DT
detection_NOMZ
of_PIN
gamma_NN
rays_NN
photons_NN
emitted_VBN [WZPAST]
by_PIN
radiopharmaceuticals_NN
tomography_JJ
stenosis_NN
narrowing_GER
of_PIN
the_DT
blood_NN
vessels_NN
._.
Restenosis_NN
is_VPRT [BEMA]
the_DT
re-narrowing_GER
of_PIN
the_DT
blood_NN
vessels_NN
after_IN
initial_JJ
treatment_NOMZ
of_PIN
coronary_JJ
artery_NN
disease_NN
stent_VBD
a_DT
small_JJ
tube_NN
inserted_VBN [WZPAST]
into_PIN
a_DT
blood_NN
vessel_NN
to_TO
prevent_VB
restenosis_NN
thrombus_NN
a_DT
blood_NN
clot_NN
formed_VBD
within_PIN
a_DT
blood_NN
vessel_NN
and_CC
remaining_VBG
attached_VBN
to_PIN
its_PIT
point_NN
of_PIN
origin_NN
toxicology_NN
the_DT
study_NN
of_PIN
the_DT
effect_NN
of_PIN
foreign_JJ
substances_NN
on_PIN
the_DT
body_NN
and_CC
its_PIT
functioning_VBG
vascular_JJ
relating_VBG
to_PIN
the_DT
blood_NN
vessels_NN
,_,
as_IN
of_PIN
the_DT
heart_NN
cardiovascular_JJ
or_CC
brain_NN
cerebrovascular_JJ
96_CD
Amersham_NN
plc_NN
Annual_JJ
Report_NN
&_CC
Accounts_NN
2002_CD
Cautionary_JJ
statement_NOMZ
for_PIN
purposes_NN
of_PIN
the_DT
safe_JJ
harbor_NN
provisions_NN
of_PIN
the_DT
United_NN
States_NN
Private_NN
Securities_NOMZ
Litigation_NOMZ
Reform_NN
Act_NN
of_PIN
1995_CD
._.
The_DT
Private_JJ
Securities_NOMZ
Litigation_NOMZ
Reform_NN
Act_NN
of_PIN
1995_CD
provides_VPRT
for_PIN
a_DT
safe_JJ
harbor_NN
for_PIN
forward-looking_JJ
statements_NOMZ
._.
This_DEMO
Annual_JJ
Report_NN
contains_VPRT
words_NN
such_JJ
as_IN
believe_VPRT [PRIV]
,_,
expect_VPRT [PRIV]
and_PHC
anticipate_VPRT [PRIV]
and_CC
similar_JJ
expressions_NN
,_,
that_DEMP
identify_VB
forward-looking_JJ
statements_NOMZ
,_,
which_WDT [SERE]
reflect_VPRT [PRIV]
the_DT
groups_NN
views_NN
about_IN
future_JJ
events_NN
and_CC
financial_JJ
performance_NN
._.
Such_JJ
forward-looking_JJ
statements_NOMZ
relate_VPRT
to_PIN
the_DT
outlook_NN
of_PIN
Amersham_NN
plc_NN
,_,
including_VBG [PRESP]
in_CONJ
particular_NULL
,_,
the_DT
expected_VBN [PRIV]
growth_NN
of_PIN
certain_JJ
of_PIN
the_DT
groups_NN
products_NN
or_CC
the_DT
markets_NN
for_PIN
those_DEMO
products_NN
and_CC
the_DT
impact_NN
of_PIN
currency_NN
movements_NOMZ
during_PIN
2003_CD
._.
Actual_JJ
results_NN
could_POMD
differ_VB
materially_RB
from_PIN
those_DEMP
projected_VBN
in_PIN
such_JJ
forward_RB
looking_VBG
statements_NOMZ
as_CONJ
a_NULL
result_NULL
of_PIN
various_JJ
factors_NN
that_TSUB
may_POMD
be_VB
beyond_IN
the_DT
control_NN
of_PIN
the_DT
group_NN
._.
The_DT
following_VBG
important_JJ
factors_NN
could_POMD
cause_VB
actual_JJ
results_NN
to_TO
differ_VB
materially_RB
from_PIN
those_DEMP
projected_VBN
or_CC
implied_VBN [PRIV]
in_PIN
any_QUAN
forwardlooking_VBG
statements_NOMZ
:_:
i_FPP1
changes_NN
in_PIN
demand_NN
for_PIN
the_DT
products_NN
of_PIN
Amersham_NN
plc_NN
worldwide_NN
or_CC
the_DT
markets_NN
for_PIN
those_DEMO
products_NN
as_RB
well_RB
as_IN
changes_NN
in_PIN
managements_NOMZ
expectation_NOMZ
of_PIN
the_DT
development_NOMZ
of_PIN
new_JJ
markets_NN
and_CC
the_DT
timing_NN
of_PIN
completion_NOMZ
of_PIN
various_JJ
trials_NN
leading_VBG [WZPRES]
to_PIN
the_DT
introduction_NOMZ
of_PIN
new_JJ
products_NN
:_:
ii_FW
changes_NN
in_PIN
the_DT
cost_NN
or_CC
supply_NN
of_PIN
raw_JJ
materials_NN
,_,
changes_NN
in_PIN
interest_NN
rates_NN
and_CC
the_DT
impact_NN
of_PIN
competition_NOMZ
:_:
iii_FW
price_NN
controls_NN
and_PHC
price_NN
reductions_NOMZ
,_,
fluctuations_NOMZ
in_PIN
exchange_NN
rates_NN
for_PIN
foreign_JJ
currencies_NN
,_,
changes_NN
in_PIN
governmental_JJ
regulation_NOMZ
,_,
and_ANDC
the_DT
risk_NN
of_PIN
loss_NN
of_PIN
patents_NN
or_CC
trademarks_NN
._.
Accordingly_RB
,_,
readers_NN
are_VPRT [PASS]
cautioned_VBN
not_XX0
to_TO
place_VB
undue_JJ
reliance_NN
on_PIN
these_DEMO
forward-looking_JJ
statements_NOMZ
._.
In_CONJ
any_NULL
event_NULL
,_,
these_DEMO
statements_NOMZ
speak_VPRT
only_DWNT
as_IN
of_PIN
the_DT
date_NN
on_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [PASS]
made_VBN
,_,
and_ANDC
the_DT
group_NN
does_VPRT
not_XX0
undertake_VB
any_QUAN
obligation_NOMZ
to_TO
update_VB
or_CC
revise_VB
any_QUAN
of_PIN
them_TPP3
,_,
whether_IN
as_CONJ
a_NULL
result_NULL
of_PIN
new_JJ
information_NOMZ
,_,
future_JJ
events_NN
or_CC
otherwise_CONJ
._.
Amersham_NN
,_,
Amersham_NN
Health_NN
,_,
Amersham_NN
Biosciences_NN
,_,
KTA_NN
,_,
KTApilot_NN
,_,
Chromaflow_NN
,_,
CodeLink_NN
,_,
CyDye_NN
,_,
DaTSCAN_NN
,_,
EchoSeed_NN
,_,
Ettan_NN
,_,
GenomiPhi_NN
,_,
Helispin_NN
,_,
Imanet_NN
,_,
LEADseeker_NN
,_,
Ludicea_NN
,_,
MegaBACE_NN
,_,
MabSelect_NN
,_,
Myoview_NN
,_,
OligoProcess_NN
,_,
Omnipaque_NN
,_,
Omniscan_NN
,_,
OncoSeed_NN
,_,
Optison_NN
,_,
Rapid_NN
Strand_NN
,_,
Scierra_NN
,_,
Sepharose_NN
,_,
Sonazoid_NN
,_,
Source_NN
,_,
Spin_NN
Signal_NN
,_,
Streamline_NN
,_,
TempliPhi_NN
and_PHC
Visipaque_NN
are_VPRT
trademarks_NN
of_PIN
Amersham_NN
plc_NN
TheraSeed_NN
is_VPRT [BEMA]
a_DT
trademark_NN
of_PIN
Theragenics_NN
Corp_NN
Amersham_NN
plc_NN
2003_CD
All_QUAN
rights_NN
reserved_VBN
All_QUAN
goods_NN
and_PHC
services_NN
are_VPRT [PASS]
sold_VBN
subject_JJ
to_PIN
the_DT
terms_NN
and_PHC
conditions_NOMZ
of_PIN
sale_NN
of_PIN
the_DT
company_NN
within_PIN
the_DT
Amersham_NN
group_NN
which_WDT [WHSUB]
supplies_VPRT
them_TPP3
._.
A_DT
copy_NN
of_PIN
these_DEMO
terms_NN
and_PHC
conditions_NOMZ
is_VPRT [BEMA]
available_PRED
on_PIN
request_NN
._.
Amersham_NN
plc_NN
,_,
Amersham_NN
Place_NN
,_,
Little_NN
Chalfont_NN
,_,
Buckinghamshire_NN
,_,
England_NN
HP7_NN
9NA_NN
Mega_JJ
Matt_NN
is_VPRT [PASS]
made_VBN
from_PIN
50_CD
%_NN
TCF_NN
and_CC
50_CD
%_NN
recycled_JJ
fiber_NN
in_PIN
accordance_NN
with_PIN
the_DT
Nordic_NN
Swan_NN
Environmental_NN
Standard_NN
._.
Designed_VBN [PASTP]
by_PIN
Merchant_NN
with_PIN
navyblue_JJ
Typeset_NN
by_PIN
Saffron_NN
Digital_NN
Production_NOMZ
Printed_NN
by_PIN
St_NN
Ives_NN
Westerham_NN
Press_NN
Amersham_NN
plc_NN
Amersham_NN
Place_NN
Little_NN
Chalfont_NN
Buckinghamshire_NN
HP7_NN
9NA_NN
England_NN
www_NN
._.
com_NN
Registered_NN
in_PIN
England_NN
and_PHC
Wales_NN
1002610_CD
